Metraipolis › archive › dc_91db05c91d64

Effectiveness and Safety of Combined Semaglutide and Dapagliflozin Therapy in Type 2 Diabetes: A Retrospective Cohort Study — Europe PMC PMID:42583162

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42583162
DOI
10.7759/cureus.112523
License (as archived)
solo-consultazione
Archived
2026-10-18T07:57:57.820Z
SHA-256 of the archived text
375dbadb98ddd0995adfd8836c049d2abe85ef290ec00da118a2d43c1ad55983
Stable URL of this page
https://metraipolis.com/documento/dc_91db05c91d64

How to cite

Effectiveness and Safety of Combined Semaglutide and Dapagliflozin Therapy in Type 2 Diabetes: A Retrospective Cohort Study — Europe PMC PMID:42583162 — Europe PMC (en), https://europepmc.org/article/MED/42583162 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_91db05c91d64 (Metraipolis archive dc_91db05c91d64, sha256 375dbadb98ddd0995adfd8836c049d2abe85ef290ec00da118a2d43c1ad55983)
BibTeX
@misc{dc91db05c91d64,
  title = {Effectiveness and Safety of Combined Semaglutide and Dapagliflozin Therapy in Type 2 Diabetes: A Retrospective Cohort Study — Europe PMC PMID:42583162},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42583162},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_91db05c91d64; sha256 375dbadb98ddd0995adfd8836c049d2abe85ef290ec00da118a2d43c1ad55983},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42583162. Agents can read the archived copy with the MCP tool read_document.